Treatment of engineered recombinant FGF21 (LY2405319) for 1 month has been tested for its improvement of LDL-C, HDL-C, triglycerides, body weight, blood adiponectin, and β-hydroxybutyrate levels in obese patients with type 2 diabetes (Gaich et al., 2013). The gene discussed is FGF21; the disease is type 2 diabetes mellitus.